187 related articles for article (PubMed ID: 24954171)
1. Toward rapid, high-sensitivity, volume-constrained biomarker quantification and validation using backscattering interferometry.
Olmsted IR; Hassanein M; Kussrow A; Hoeksema M; Li M; Massion PP; Bornhop DJ
Anal Chem; 2014 Aug; 86(15):7566-74. PubMed ID: 24954171
[TBL] [Abstract][Full Text] [Related]
2. Compensated Interferometry Measures of CYFRA 21-1 Improve Diagnosis of Lung Cancer.
Kammer MN; Kussrow AK; Webster RL; Chen H; Hoeksema M; Christenson R; Massion PP; Bornhop DJ
ACS Comb Sci; 2019 Jun; 21(6):465-472. PubMed ID: 31022347
[TBL] [Abstract][Full Text] [Related]
3. Novel enzyme-free immunomagnetic microfluidic device based on Co
Proença CA; Baldo TA; Freitas TA; Materón EM; Wong A; Durán AA; Melendez ME; Zambrano G; Faria RC
Anal Chim Acta; 2019 Sep; 1071():59-69. PubMed ID: 31128756
[TBL] [Abstract][Full Text] [Related]
4. Quantification of CYFRA 21-1 and a CYFRA 21-1-anti-CYFRA 21-1 autoantibody immune complex for detection of early stage lung cancer.
Song KS; Nimse SB; Warkad SD; Oh AC; Kim T; Hong YJ
Chem Commun (Camb); 2019 Aug; 55(68):10060-10063. PubMed ID: 31328750
[TBL] [Abstract][Full Text] [Related]
5. Diagnosing the RGS11 Lung Cancer Biomarker: The Integration of Competitive Immunoassay and Isothermal Nucleic Acid Exponential Amplification Reaction.
Chang YF; Huang YQ; Wu KM; Jou AF; Shih NY; Ho JA
Anal Chem; 2019 Mar; 91(5):3327-3335. PubMed ID: 30701963
[TBL] [Abstract][Full Text] [Related]
6. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.
Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J
Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790
[TBL] [Abstract][Full Text] [Related]
7. Nanoporous Glass Integrated in Volumetric Bar-Chart Chip for Point-of-Care Diagnostics of Non-Small Cell Lung Cancer.
Li Y; Xuan J; Song Y; Qi W; He B; Wang P; Qin L
ACS Nano; 2016 Jan; 10(1):1640-7. PubMed ID: 26690745
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic validation and interpretation of longitudinal circulating biomarkers using a biomarker response characteristic plot.
Moritz R; Muller M; Korse CM; van den Broek D; Baas P; van den Noort V; Ten Hoeve JJ; van den Heuvel MM; van Rossum HH
Clin Chim Acta; 2018 Dec; 487():6-14. PubMed ID: 30201371
[TBL] [Abstract][Full Text] [Related]
9. A novel immunoassay for the quantization of CYFRA 21-1 in human serum.
He A; Liu TC; Dong ZN; Ren ZQ; Hou JY; Li M; Wu YS
J Clin Lab Anal; 2013 Jul; 27(4):277-83. PubMed ID: 23852784
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous quantitation of cytokeratin-19 fragment and carcinoembryonic antigen in human serum via quantum dot-doped nanoparticles.
Chen Z; Liang R; Guo X; Liang J; Deng Q; Li M; An T; Liu T; Wu Y
Biosens Bioelectron; 2017 May; 91():60-65. PubMed ID: 27988480
[TBL] [Abstract][Full Text] [Related]
11. Additional diagnostic value of tumor markers in cytological fluid for diagnosis of non-small-cell lung cancer.
Hur J; Lee HJ; Nam JE; Kim YJ; Hong YJ; Kim HY; Kim SK; Chang J; Kim JH; Chung KY; Lee HS; Choi BW
BMC Cancer; 2012 Sep; 12():392. PubMed ID: 22954172
[TBL] [Abstract][Full Text] [Related]
12. Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers.
Li BT; Lou E; Hsu M; Yu HA; Naidoo J; Zauderer MG; Sima C; Johnson ML; Daras M; DeAngelis LM; Fleisher M; Kris MG; Azzoli CG
PLoS One; 2016; 11(1):e0146063. PubMed ID: 26730601
[TBL] [Abstract][Full Text] [Related]
13. [Stem cell factor (SCF) in diagnosis and monitoring of non-small-cell lung cancer].
Mroczko B; Szmitkowski M; Czygier M
Pol Arch Med Wewn; 1999 Mar; 101(3):213-8. PubMed ID: 10697397
[TBL] [Abstract][Full Text] [Related]
14. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
15. Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung.
Muley T; He Y; Rolny V; Wehnl B; Escherich A; Warth A; Stolp C; Schneider MA; Meister M; Herth FJ; Dayyani F
Lung Cancer; 2019 Apr; 130():194-200. PubMed ID: 30885344
[TBL] [Abstract][Full Text] [Related]
16. Cytokeratin-19 fragments, nucleosomes and neuron-specific enolase as early measures of chemotherapy response in non-small cell lung cancer.
Alm El-Din MA; Farouk G; Nagy H; Abd Elzaher A; Abo El-Magd GH
Int J Biol Markers; 2012 Jul; 27(2):e139-46. PubMed ID: 22467097
[TBL] [Abstract][Full Text] [Related]
17. Assay Performance of a Label-Free, Solution-Phase CYFRA 21-1 Determination.
Kussrow AK; Kammer MN; Massion PP; Webster R; Bornhop DJ
ACS Omega; 2022 Sep; 7(36):31916-31923. PubMed ID: 36120008
[TBL] [Abstract][Full Text] [Related]
18. A magnetic nanoparticle-based time-resolved fluoroimmunoassay for determination of the cytokeratin 19 fragment in human serum.
Lin G; Liu T; Hou J; Ren Z; Zhou J; Liang Q; Chen Z; Dong W; Wu Y
J Fluoresc; 2015 Mar; 25(2):361-7. PubMed ID: 25666714
[TBL] [Abstract][Full Text] [Related]
19. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
[TBL] [Abstract][Full Text] [Related]
20. Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma.
Huang L; Chen W; Liang P; Hu W; Zhang K; Shen S; Chen J; Zhang Z; Chen B; Han Y; Meng F; DeMorrow S; Yin X; Lai J; Liang L
Dig Dis Sci; 2015 May; 60(5):1273-83. PubMed ID: 25487191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
